These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7866205)

  • 1. New treatments for multiple sclerosis.
    McDonald WI
    BMJ; 1995 Feb; 310(6976):345-6. PubMed ID: 7866205
    [No Abstract]   [Full Text] [Related]  

  • 2. Options for multiple sclerosis therapy.
    Cotton P
    JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404
    [No Abstract]   [Full Text] [Related]  

  • 3. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 4. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 8. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More immunotherapy for multiple sclerosis.
    Hughes RA; Sharrack B
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592
    [No Abstract]   [Full Text] [Related]  

  • 13. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 14. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon beta-1A for multiple sclerosis.
    Drug Ther Bull; 1998 Jan; 36(1):7-8. PubMed ID: 9614724
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy in multiple sclerosis.
    Tullman MJ; Lublin FD
    Curr Neurol Neurosci Rep; 2005 May; 5(3):245-8. PubMed ID: 15865891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in quality of life in patients with remitted multiple sclerosis during the specific treatment with disease-modifying drugs: a comparative study of populations of Moscow and Novosibirsk].
    Popova EV; Riabukhina OV; Vorob'eva OV; Malkova NA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):67-70. PubMed ID: 21322129
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of cognitive impairment in multiple sclerosis.
    Pierson SH; Griffith N
    Behav Neurol; 2006; 17(1):53-67. PubMed ID: 16720960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.